Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2019 October;110(5) > Minerva Medica 2019 October;110(5):455-63

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Medica 2019 October;110(5):455-63

DOI: 10.23736/S0026-4806.19.06068-3

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Efficacy and tolerability of a fixed dose combination of cortex phospholipid liposomes and cyanocobalamin for intramuscular use in peripheral neuropathies

Giulia LETIZIA MAURO 1 , Lorenza LAURICELLA 1, Michele VECCHIO 2, Sofia TOMASELLO 3, Dalila SCATURRO 1

1 Department of Surgery, Oncology, and Stomatology, University of Palermo, Palermo, Italy; 2 Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy; 3 University of Palermo, Palermo, Italy



Peripheral neuropathies are frequently encountered in clinical practice and are associated with a major impairment in quality of life. However, their management remains poor, and current therapies are often burdened with major side effects and can present poor efficacy on pain and functionality. Therefore, it has been suggested that the combination of two or more different drugs may improve analgesic efficacy and reduce side effects. Tricortin® 1000 is formulated with 12 mg of Brain cortex phospholipid liposomes + 1000 µg of Cyanocobalamin injectable solution (PL+CNCbl) for intramuscular use and is indicated in the treatment of poly-algo-neuropathic syndromes. This combination exerts a marked neurotrophic action by promoting the synthesis of endogenous phospholipids; moreover, the peculiar formulation optimizes the delivery of CNCbl which has analgesic and neurotrophic action. This paper discusses the pharmacotherapy of peripheral neuropathies, including low-back pain, neck pain, postherpetic neuropathy (PHN) and focuses on the fixed dose combination PL+CNCbl clinical efficacy in association with other treatments or in monotherapy.


KEY WORDS: Back pain; Neuralgia; Peripheral nervous system diseases; Phospholipids; Liposomes; Vitamin B12

top of page